Mexico’s antitrust body on Monday said it had made local approval of an asset swap between French drugmaker Sanofi and Germany’s Boehringer Ingelheim conditional on Sanofi not acquiring its peer’s cough medicines in Mexico.
Mexico’s Federal Economic Competition Commission said in a statement that a proposed merger of Sanofi and Boehringer Ingelheim assets in Mexico would give Sanofi the capacity to fix prices or restrict supplies of cough medicines.
The agency said the merger in Mexico would take away leading cough market seller Sanofi’s closest competitor and increase its market share even more over smaller competitors.
The agency, known as COFECE, said the swap would only be authorized if Sanofi did not buy three brands of cough medicine, Bisolvon, Mucosolvan and Sekretovit.
Sanofi’s bid for Boehringer’s consumer health unit is part of a $20-billion asset swap, with the German company taking over its animal health arm, that has already received approval from European Union antitrust authorities.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI